Pharmaceutical firm expands in US market
When reporting its strong set of full-year figures for 2008, back in February, the Dublin-based clinical trials, medical devices and general outsourced pharmaceutical services specialist said that it was positive “though cautious” about this year. Yesterday, that outlook was vindicated, at the earliest opportunity, with a 9% increase in first-quarter revenue to $219.8 million (€169.3m) and a 25% rise in operating profits and earnings per share to $26.9m and 35c respectively. The value of new business wins for the three months to the end of March amounted to $265m.
Icon also announced yesterday that it has acquired a 33,000sq ft Phase 1 testing facility, with a capacity of up to 100 beds, in Omaha, Nebraska, as part of the assets acquired from US company, Qualia Clinical Services.
